New trial
Pilot Study of Tamoxifen (Estrogen Receptor Inhibitor) in Pre-Invasive Pancreas MCN
- Trial ID
- NCT06320990 on ClinicalTrials.gov
- Cancer type
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Published in
- New in Oncology - May 29, 2025
The University of Nebraska is conducting an open‐label pilot study enrolling up to 15 participants with pancreatic MCN who won't undergo immediate resection, to assess the feasibility of 20mg daily tamoxifen over 6 months with response evaluation by MRI.
More in pancreatic cancer
-
Trial result · Oct 15, 2026 · NCT04543071
Motixafortide (CXCR4 inhibitor) + cemiplimab (PD-1) + gem/nab-paclitaxel posts 55% confirmed ORR in 1L metastatic PDAC -
Trial result · Oct 15, 2026 · NCT06850623
ACT (PS101 + focused ultrasound) plus mFOLFIRINOX shows early responses and a resection conversion signal in locally advanced/borderline PDAC -
Trial result · Oct 15, 2026 · NCT07562152
Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer -
New trial · Oct 15, 2026 · NCT07619521
Phase 1/2 selumetinib plus trastuzumab deruxtecan targets KRAS-mutant, HER2-expressing pancreatic cancer -
New trial · Oct 15, 2026 · NCT07824960
Phase 1b/2 avutometinib plus defactinib adds RAF/MEK and FAK inhibition to mFOLFIRINOX in pancreatic cancer